机构:[1]Traditional Chinese Medicine, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.[2]State Institution of Drug Clinical Trials, and Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.[3]Department of Pharmacy, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.
Background:
Hepatocellular carcinoma (HCC) poses a growing threat to humans due to poor prognosis. Extract of stellera chamaejasme L. (ESC) is reported to inhibit metastasis of HCC. However, the underlying mechanism of ESC in regulating the progression of HCC needs to be further investigated.
Methods:
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) assay was used to measure cell proliferation. Flow cytometry was employed to check cell apoptosis. Transwell assay was conducted to assess the abilities of cell migration and invasion. The protein levels of proliferating cell nuclear antigen, cleaved caspase 3 (c-caspase 3), E-cadherin, janus kinase 1 (JAK1), signal transducer and activator of transcription 3 (STAT3), and phosphorylated STAT3 were detected by Western blot. The interaction between miR-134-5p and JAK1 was predicted by starBase, which was verified by the dual-luciferase reporter assay and RNA pull-down assay. The messenger RNA levels of miR-134-5p and JAK1 were determined by quantitative real-time polymerase chain reaction.
Results:
The results showed that the higher concentration or the longer time treatment of ESC led to the lower survival rate of HCC cells. Besides, ESC induced apoptosis and impeded migration and invasion of HCC cells. Moreover, downregulation of miR-134-5p inverted the effects of ESC-mediated repression on HCC progression. Further studies indicated that miR-134-5p targeted the 3'-untranslated region (3'UTR) of JAK1 and reversed JAK1-mediated impacts on HCC progression. Simultaneously, ESC inactivated JAK1/STAT3 pathway by regulating the expression of miR-134-5p.
Conclusion:
ESC suppressed HCC progression by upregulating the expression of miR-134-5p and blocking JAK1/STAT3 pathway.
基金:
Special fund for medical and
health development on inheriting and developing of Traditional
Chinese Medicine in 2018 (Guangdong Traditional
Chinese Medicine Office [2018] No.5).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区肿瘤学4 区药学4 区核医学
最新[2025]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区肿瘤学4 区药学4 区核医学
第一作者:
第一作者机构:[1]Traditional Chinese Medicine, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.
通讯作者:
通讯机构:[3]Department of Pharmacy, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.[*1]Department of Pharmacy, Guangdong Second Provincial General Hospital, No. 466, Xinggang Middle Road Haizhu District, Guangzhou, Guangzhou 510317, Guangdong, China
推荐引用方式(GB/T 7714):
Huang Xiaoqing,Chen Yan,Zhang Xia,et al.Extract of Stellera Chamaejasme L. Inhibits the Progression of Hepatocellular Carcinoma by Regulating miR-134-5p and JAK1/STAT3 Pathway.[J].Cancer biotherapy & radiopharmaceuticals.2020,35(8):586-595.doi:10.1089/cbr.2019.3229.
APA:
Huang Xiaoqing,Chen Yan,Zhang Xia,Li Feifeng&Ye Haoting.(2020).Extract of Stellera Chamaejasme L. Inhibits the Progression of Hepatocellular Carcinoma by Regulating miR-134-5p and JAK1/STAT3 Pathway..Cancer biotherapy & radiopharmaceuticals,35,(8)
MLA:
Huang Xiaoqing,et al."Extract of Stellera Chamaejasme L. Inhibits the Progression of Hepatocellular Carcinoma by Regulating miR-134-5p and JAK1/STAT3 Pathway.".Cancer biotherapy & radiopharmaceuticals 35..8(2020):586-595